AVTE | Aerovate Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	2.6400 - 2.7150
52 Week Range	1.2500 - 32.42
Beta	1.45
Implied Volatility	94.42%
IV Rank	36.43%
Day's Volume	386,978
Average Volume	784,644
Shares Outstanding	28,874,500
Market Cap	76,806,170
Sector	Healthcare
Industry	Biotechnology
IPO Date	2021-06-30

Valuation
Profitability
Growth
Health
P/E Ratio	-0.89
Forward P/E Ratio	N/A
EPS	-2.99
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	51
Country	USA
Website	AVTE

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

AVTE's peers: AADI, ACET, ACIU, ACXP, ADAG, ADVM, ANTX, ALVR, ALXO, ANEB, ANIX, ATXS, AURA, ACRV, RZLT, OPT, MLYS, AVTX, BCAB, BCDA, BNOX, CADL, PTIX, CDXC, CELC, CING, CLDX, CSBR, FENC, CMPX, GNFT, GNTA, IKNA, IMNM, IMTX, INMB, IPA, JANX, KROS, LVTX, MDWD, MNOV, MNPR, MRKR, NVCT, OMGA, PRTG, REPL, SLGL, SNDX, STRO, SVRA, XLO, MLTX, BLTE, ELVN, GRI

*Chart delayed

Analyzing fundamentals for AVTE we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see AVTE Fundamentals page.

Watching at AVTE technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on AVTE Technicals page.